Brief: Ionis Partner Biogen Announces Topline Results From Phase 2 Celia Study Of Diranersen
14/05/2026 12:05
May 14 (Reuters) - Ionis Pharmaceuticals Inc IONS.O: IONIS PARTNER BIOGEN ANNOUNCES TOPLINE RESULTS FROM PHASE 2 CELIA STUDY OF DIRANERSEN (BIIB080): FIRST STUDY TO SHOW REDUCTION IN TAU PATHOLOGY AND COGNITIVE BENEFIT IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Source text: ID:nBw5Mb3ya Further company coverage: IONS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ionis Pharmaceuticals
See all newsAnalysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Brief: Ionis Announces License Agreement With Recordati For Zilganersen In Alexander Disease (Axd) In All Countries Outside The U.S.
Brief: Ionis Pharmaceuticals Says FDA Approved Tryngolza For Severe Hypertriglyceridemia
Brief: FDA Approves Treatment To Reduce Risk Of Acute Pancreatitis In Adults With Severe Hypertriglyceridemia
Brief: Ionis Announces Appointment Of Ludwig Hantson, Ph.D. To Board Of Directors